NextCure/$NXTC
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About NextCure
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
Ticker
$NXTC
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
43
ISIN
US65343E1082
Website
NextCure Metrics
BasicAdvanced
$12M
-
-$1.77
1.08
-
Price and volume
Market cap
$12M
Beta
1.08
52-week high
$0.78
52-week low
$0.22
Average daily volume
275K
Financial strength
Current ratio
10.261
Quick ratio
9.784
Long term debt to equity
8.796
Total debt to equity
10.459
Profitability
EBITDA (TTM)
-50.337
Management effectiveness
Return on assets (TTM)
-36.39%
Return on equity (TTM)
-63.94%
Valuation
Price to book
0.22
Price to tangible book (TTM)
0.22
Price to free cash flow (TTM)
-0.293
Free cash flow yield (TTM)
-341.29%
Free cash flow per share (TTM)
-148.73%
Growth
Earnings per share change (TTM)
-22.64%
3-year earnings per share growth (CAGR)
-12.68%
NextCure News
AllArticlesVideos
NextCure signs up to $745 million deal with China's Simcere to develop cancer drug
Reuters·3 weeks ago
NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6
GlobeNewsWire·3 weeks ago
NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for NextCure stock?
NextCure (NXTC) has a market cap of $12M as of July 05, 2025.
What is the P/E ratio for NextCure stock?
The price to earnings (P/E) ratio for NextCure (NXTC) stock is 0 as of July 05, 2025.
Does NextCure stock pay dividends?
No, NextCure (NXTC) stock does not pay dividends to its shareholders as of July 05, 2025.
When is the next NextCure dividend payment date?
NextCure (NXTC) stock does not pay dividends to its shareholders.
What is the beta indicator for NextCure?
NextCure (NXTC) has a beta rating of 1.08. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.